Partnerre Trigger Pharmaceuticals (At 2.16.21) Code Brand Name Trade Name Code Brand Name Trade Name J0800 Acthar®

Home , Lumasiran, Necitumumab, Teprotumumab, Umbralisib

PartnerRe Trigger Pharmaceuticals (at 2.16.21) Code Brand Name Trade Name Code Brand Name Trade Name J0800 Acthar® ...... repository corticotropin injection J3590 Danyelza®...... naxitamab-gqgk J9216 Actimmune®...... interferon gamma-1B J9145 Darzalex Faspro®...... daratumumab J9042 Adcetris®...... brentuximab vedotin J8999 Daurismo®...... glasdegib J7192 Advate®...... factor viii recombinant nos J8499 Demser®...... metyrosine J7207 Adynovate®...... antihemophilia factor viii, pegylated J1743 Elaprase® ...... idursulfase J7210 Afstyla®...... recombinant human factor viii J3060 Elelyso® ...... taliglucerace alfa J1931 Aldurazyme® ...... laronidase J7205 Eloctate®...... antihemophilic factor viii J8999 Alecensa®...... alectinib J3590 Elzonris® ...... tagraxofusp-erzs J7186 Alphanate®...... von Willebrand Factor Complex/ J9176 Empliciti®...... elotuzumab antihemophilic J3590 Enspryng®...... satralizumab-mwge J7201 Alprolix®...... factor ix recombinant J9055 Erbitux®...... cetuximab J8999 Alunbrig®...... brigatinib J7192 Esperoct®...... factor viii recombinant nos J9302 Arzerra®...... ofatumumab Evkeeza®...... evinacumab-dgnb J1599 Asceniv®...... immune globulin-slra J3590 Evrysdi® ...... risdiplam J7196 Atryn®...... antithrombin recombinant J1428 Exondys 51® ...... eteplirsen J7198 Autoplex T F®...... factor ix anti-inhibitor J0180 Fabrazyme®...... agalsidase beta coagulant complex J7198 Feiba NF®...... anti-inhibitor coagulant complex* J9035 Avastin®...... bevacizumab J1744 Firazyr®...... icatibant J8999 Ayvakit®...... avapritinib J8499 Firdapse® ...... amifampridine C9399 Azedra® ...... Iobenguane I 131 J9307 Folotyn® ...... pralatrexate J8999 Balversa® ...... erdafitinib J8499 Galafold® ...... migalastat J9032 Beleodaq®...... belinostat J3590 Gamifant® ...... emapalumab-izsg

J7195 BeneFIX®...... factor ix recombinant J1569 Gammagard Liquid®...... IVIG Immune globulin J0597 Berinert® ...... C1 esterase inhibitor concentrate J1566 Gammagard®...... IVIG Immune globulin J7599 Blenrep® ...... belantamab mafodotin-blmf J1561 Gammaked®...... IVIG Immune globulin J9039 Blincyto®...... blinatomumab J1557 Gammaplex®...... IVIG Immune globulin J3590 Breyanzi®...... lisocabtagene maraleucel J1561 Gamunex-C®...... IVIG Immune globulin J0567 Brineura®...... cerliponase alfa J3490 Gattex® ...... teduglutide J8999 Brukinsa® ...... zanubrubtinib C9056 Givlaari®...... givosiran J3590 Cablivi® ...... caplacizumab-yhdp J0599 Haegarda® ...... C1 esterase inhibitor subcutaneous J8999 Cabometyx®...... cabozantinib J7192 Helixate®...... factor viii recombinant nos J8999 Calquence®...... acalabrutinib J7170 Hemlibra®...... emicizumab-kxwh J8499 Carbaglu® ...... carglumic acid J1559 Hizentra®/Hizentra 20%...... immune globulin J1566 Carimune NF®...... IVIG immune globulin, intravenous subcutaneous, human J8499 Cerdelga® ...... eliglustat J7187 Humate-P® ...... von Willebrand Factor Complex/ J1786 Cerezyme® ...... imiglucerase antihemophilic J8499 Chenodal® ...... chenodiol J7202 Idelvion®...... factor ix recombinant J8499 Cholbam® ...... cholic acid J8999 Idhifa®...... enasidenib J0598 Cinryze® ...... C1 esterase inhibitor J0638 Ilaris®...... canakinumab J7175 Coagadex®...... coagulation factor X [human] J8999 Imbruvica®...... ibrutinib J7180 Corifact®...... factor xiii antihemophilic factor Imcivree®...... setmalanotide J0584 Crysvita®...... burosumab-twza J9173 Imfinzi®...... durvalumab J8499 Cuprimine®...... penicillamine J8999 Inqovi®...... decitabine and cedazuridine J9308 Cyramza®...... ramucirumab J8999 Inrebic®...... fedratinib

PartnerRe America Insurance Company PartnerRe Health is a division of PartnerRe Ltd. In the U.S, coverage is underwritten 6900 Wedgwood Road North PartnerRe Health is a division of PartnerRe Ltd. In the U.S, coverage is underwritten SuitePartnerRe 120 American Insurance Company by PartnerRe America Insurance Company. This Literature is descriptive only. Actual Maple Grove, MN 55311 Coverageby PartnerRe is subject America to Insurancethe language Company. of the policies This Literature or agreements is descriptive issued. only. Actual USAPhone +1 415 354 1551 Coverage is subject to the language of the policies or agreements issued. Phonewww.partnerre.com/health +1 612 234 4920 www.partnerre.com/health TRX021621TRX02162 | 21 of0f 33 PartnerRe Trigger Pharmaceuticals (at 2.16.21) Code Brand Name Trade Name Code Brand Name Trade Name J9315 Istodax® ...... romidepsin J8499 Orladeyo® ...... berotrastat J9280 Jelmyto®...... mitomycin/mitomycin-C J8999 Oxlumo®...... lumasiran J7208 Jivi®...... factor viii recombinant nos J3490 Palynziq®...... pegvalise-pqpz J8499 Juxtapid®...... lomitapide J8999 Pemazyre®...... pemigatinib J9354 Kadcyla®...... ado-trastuzumab emtansine J9295 Portrazza®...... necitumumab J1290 Kalbitor® ...... ecallantide J9204 Poteligeo® ...... mogamulizumab-kpkc J8499 Kalydeco® ...... ivacaftor J1459 Privigen®...... IVIG Immune globulin J2840 Kanuma®...... sebelipase alfa J7194 Profilnine®...... factor ix complex J9271 Keytruda®...... pembrolizumab J8999 Qinlock®...... ripretinib J7190 Koate®...... factor viii J1301 Radicava®...... edaravone J7192 Kogenate®...... factor viii recombinant nos J8499 Ravicti® ...... glycerol phenylbutyrate J8499 Korlym®...... mifepristone J7203 Rebinyn®...... factor ix antihemophilic factor J8499 Koselugo®...... selumetinib J7192 Recombinate® ...... factor viii recombinant nos J7211 Kovaltry®...... recombinant human factor viii J8999 Retevmo®...... selpercatinib J2507 Krystexxa®...... pegloticase J3590 Revcovi® ...... elapegademase-lvlr Q2042 Kymriah® ...... tisagenlecleucel J7178 Riastap®...... fibrinogen concentrage [human] J9285 Lartruvo®...... olaratumab J7200 Rixubis® ...... factor ix recombinant J3590 Libtayo® ...... cemiplimab-rwlc J7185 Roctavian®...... valoctocogene roxaparvovec J8999 Lorbrena®...... lorlatinib J0596 Ruconest® ...... C1 esterase inhibitor recombinant J0221 Lumizyme®...... alglucosidase alfa J8499 Ruzurgi®...... amifampridine J3590 Lumoxiti®...... moxetumomab pasudotox-tdfk J8499 Sabril®...... vigabatrin J8499 Lupkynis®...... voclosporin J3590 Sogroya®...... somapacitan-beco J3490 Lutathera®...... lutetium lu 177 dotatate J1300 Soliris® ...... eculizumab J3398 Luxturna® ...... voretigene neparvovec-rzyl J2326 Spinraza® ...... nusinersen J8999 Lynparza®...... olaparib J3357 Stelara®...... ustekinumab J8999 Mekinist®...... trametinib J8999 Stivarga®...... regorafenib J3397 Mepsevii® ...... vestronidase alfa-vjbk J3590 Strensiq® ...... asfotase alfa J7599 Monjuvi®...... tafasitamab-cxix J2860 Sylvant®...... siltuximab J7190 Monoclate-P®...... factor viii, human J8499 Symdeko®...... tezacaftor/ivacaftor and ivacaftor Q5107 Mvasi®...... bevacizumab awwb J8999 Tabrecta®...... capmatinib hydrochloride J3590 Myalept® ...... metreleptin J3590 Tafamidis®...... Vyndaqel J1458 Naglazyme®...... galsulfase J8999 Tafinlar®...... dabrafenib mesylate J7182 NovoEight®...... factor viiii recombinant J3590 Takhzyro® ...... lanadelumab-flyo J7189 NovoSeven RT®...... recombinant human factor viia J8999 Targretin®...... bexarotene J2796 Nplate®...... romiplostim J8999 Tazverik®...... tazemetostat hydrobromide J2182 Nucala®...... mepolizumab J3590 Tecartus®...... brexucabtagene autoleucel J7209 Nuwiq®...... factor viii recombinant J9022 Tecentriq®...... atezolizumab J7188 Obizur®...... antihemophilia factor, recombinant J3490 Tegsedi®...... inotersen J1568 Octagam®...... IVIG Immune globulin J8999 Tepezza®...... teprotumumab-trbw J3590 Onpattro®...... patisiran J8999 Tepmetko®...... tepotinib hydrochloride hydrate J8999 Onureg®...... azacitidine J7197 Thrombate®...... antithrombin III, human J9299 Opdivo®...... nivolumab J8999 Tibsovo® ...... ivosidenib J8499 Orfadin®...... nitisinone J7181 Tretten®...... factor xiii recombinant J8499 Orkambi®...... lumacaftor/ivacaftor J8499 Trikafta®...... elexacaftor/tezacaftor/ivacaftor

The trademarks above are the property of the respective trademark owner. Members utilizing trigger pharmaceuticals should be reported to PartnerRe as per the terms of the reinsurance agreement. Reporting format and instructions can be found at: https://partnerre.com/risk-solutions/health/ in the document titled Trigger Pharmaceuticals.xlsx. Confidentiality Notice: This document is confidential, contains proprietary information and is the intellectual property of PartnerRe America Insurance Company (PRAIC). Neither this document nor any of the information contained herein may be reproduced or disclosed under any circumstances without the express written permission of PRAIC. Please be aware that any independent use of this document and the information contained therein is strictly prohibited.